Erythropoietin protects the developing retina in an ovine model of endotoxin-induced retinal injury

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2656-2661

  Loeliger, Michelle M ^a   Mackintosh, Anna ^a   de Matteo, Robert ^b   Harding, Richard ^b   Rees, Sandra M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; RECOMBINANT ERYTHROPOIETIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATHETERIZATION; CELL COUNT; DOPAMINERGIC NERVE CELL; FEMALE; FETUS; GANGLION; GESTATIONAL AGE; HYPOTENSION; HYPOXEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INTRAUTERINE INFLAMMATION; MORPHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA DEVELOPMENT; RETINA INJURY; RETINA INNER PLEXIFORM LAYER; SHEEP;

AMACRINE CELLS; ANIMALS; CELL COUNT; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN, RECOMBINANT; ESCHERICHIA COLI; FEMALE; FETAL HYPOXIA; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GESTATIONAL AGE; IMMUNOENZYME TECHNIQUES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICROGLIA; PREGNANCY; RECEPTORS, ERYTHROPOIETIN; RETINA; RETINAL DISEASES; RETINAL GANGLION CELLS; SHEEP, DOMESTIC; TYROSINE 3-MONOOXYGENASE;

EID: 79956025445     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6455     Document Type: Article

References (44)

1. Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, Guyer B. Annual summary of vital statistics: 2007. Pediatrics. 2009;125:4-15.
2. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics. 2000;106:659-671.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
4. Schendel DE, Schuchat A, Thorsen P. Public health issues related to infection in pregnancy and cerebral palsy. Ment Retard Dev Disabil Res Rev. 2002;8:39-45.
5. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997;42:1-8.
6. Dammann O, Leviton A. Inflammation, brain damage and visual dysfunction in preterm infants. Semin Fetal Neonatal Med. 2006; 11:363-368.
7. Sood BG, Madan A, Saha S, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res. 2010;67:394-400.
8. Dammann O, Brinkhaus MJ, Bartels DB, et al. Immaturity, perinatal inflammation, and retinopathy of prematurity: a multi-hit hypothesis. Early Hum Dev. 2009;85:325-329.
9. Dowdeswell HJ, Slater AM, Broomhall J, Tripp J. Visual deficits in children born at less than 32 weeks' gestation with and without major ocular pathology and cerebral damage. Br J Ophthalmol. 1995;79:447-452.
10. O'Connor AR, Stephenson TJ, Johnson A, et al. Visual function in low birthweight children. Br J Ophthalmol. 2004;88:1149-1153.
11. Robaei D, Rose KA, Kifley A, Cosstick M, Ip JM, Mitchell P. Factors associated with childhood strabismus: findings from a populationbased study. Ophthalmology. 2006;113:1146-1153.
12. Abramov I, Hainline L, Lemerise E, Brown AK. Changes in visual functions of children exposed as infants to prolonged illumination. J Am Optom Assoc. 1985;56:614-619.
13. Fauchere JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122:375-382.
14. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122:383-391.
15. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics. 2009;124:e681-e687.
16. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006;118:e635-e640.
17. Strunk T, Hartel C, Temming P, Matzke N, Zimmer J, Schultz C. Erythropoietin inhibits cytokine production of neonatal and adult leukocytes. Acta Paediatr. 2008;97:16-20.
18. Rees S, Hale N, De Matteo R, et al. Erythropoietin is neuroprotective in a preterm ovine model of endotoxin-induced brain injury. J Neuropathol Exp Neurol. 2010;69:306-319.
19. Loeliger M, Duncan J, Cock M, Harding R, Rees S. Vulnerability of dopaminergic amacrine cells and optic nerve myelination to prenatal endotoxin exposure. Invest Ophthalmol Vis Sci. 2007;48: 472-478.
20. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 1997;37:3509-3529.
21. Wang X, Rousset CI, Hagberg H, Mallard C. Lipopolysaccharideinduced inflammation and perinatal brain injury. Semin Fetal Neonatal Med. 2006;11:343-353.
22. Loeliger M, Duncan J, Louey S, Cock M, Harding R, Rees S. Fetal growth restriction induced by chronic placental insufficiency has long-term effects on the retina but not the optic nerve. Invest Ophthalmol Vis Sci. 2005;46:3300-3308.
23. Bui BV, Loeliger M, Thomas M, et al. Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. Exp Eye Res. 2009;88:1076-1083.
24. Rees S, Stringer M, Just Y, Hooper SB, Harding R. The vulnerability of the fetal sheep brain to hypoxemia at mid-gestation. Brain Res Dev Brain Res. 1997;103:103-118.
25. Mallard EC, Rees S, Stringer M, Cock ML, Harding R. Effects of chronic placental insufficiency on brain development in fetal sheep. Pediatr Res. 1998;43:262-270.
26. Archer DB, Gardiner TA. Electron microscopic features of experimental choroidal neovascularization. Am J Ophthalmol. 1981;91: 433-457.
27. Wax MB, Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol. 2002;26:45-55.
28. Mervin K, Valter K, Maslim J, Lewis G, Fisher S, Stone J. Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation. Am J Ophthalmol. 1999;128:155-164.
29. Silva-Araujo A, Abreu-Dias P, Silva MC, Tavares MA. Effects of prenatal cocaine exposure in the photoreceptor cells of the rat retina. Mol Neurobiol. 1995;11:77-86.
30. Yang P, de Vos AF, Kijlstra A. Macrophages in the retina of normal Lewis rats and their dynamics after injection of lipopolysaccharide. Invest Ophthalmol Vis Sci. 1996;37:77-85.
31. Duncan JR, Cock ML, Scheerlinck JP, et al. White matter injury after repeated endotoxin exposure in the preterm ovine fetus. Pediatr Res. 2002;52:941-949.
32. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118: 526-533.
33. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43:40-49.
34. Yasuda Y, Nagao M, Okano M, et al. Localization of erythropoietin and erythropoietin-receptor in post-implantation mouse embryos. Dev Growth Differ. 1993;35:711-722.
35. Munro K, Rees S, O'Dowd R, Tolcos M. Developmental profile of erythropoietin and its receptor in guinea-pig retina. Cell Tissue Res. 2009;336:21-29.
36. Slusarski JD, McPherson RJ, Wallace GN, Juul SE. High-dose erythropoietin does not exacerbate retinopathy of prematurity in rats. Pediatr Res. 2009;66:625-630.
37. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem. 2001;276:39469-39475.
38. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab. 2003;23:320-330.
39. Kumral A, Baskin H, Gokmen N, et al. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol Neonate. 2004;85:51-54.
40. Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N. Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama. 2001;55:357-362.
41. Ganser C, Papazoglou A, Just L, Nikkhah G. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures. Exp Cell Res. 2010;316:737-746.
42. Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience. 2007;146:1245-1258.
43. Csete M, Rodriguez L, Wilcox M, Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett. 2004;359:124-126.
44. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem. 1999;72:2565-2572.